NCT03732534View on ClinicalTrials.gov

Rollover Study for Continuing NBI-98854 Administration in Pediatric Subjects With Tourette Syndrome

PHASE2TerminatedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

October 17, 2018

Primary Completion Date

February 18, 2019

Study Completion Date

February 18, 2019

Conditions
Tourette Syndrome
Interventions
DRUG

NBI-98854

vesicular monoamine transporter 2 (VMAT2) inhibitor

Trial Locations (10)

32561

Neurocrine Clinical Site, Gulf Breeze

33013

Neurocrine Clinical Site, Hialeah

60563

Neurocrine Clinical Site, Naperville

60634

Neurocrine Clinical Site, Chicago

68526

Neurocrine Clinical Site, Lincoln

75243

Neurocrine Clinical Site, Dallas

77058

Neurocrine Clinical Site, Houston

92108

Neurocrine Clinical Site, San Diego

92805

Neurocrine Clinical Site, Anaheim

00926

Neurocrine Clinical Site, San Juan

Sponsors
All Listed Sponsors
lead

Neurocrine Biosciences

INDUSTRY